SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...

Researchers say structure reveals many new ways to change PINK1, essentially switching it on, which will be "life-changing" for people with Parkinson’s disease.

Weight loss drugs like Ozempic deliver more health benefits than expected. In a study published in the journal Life, ...

Researchers show that cordycepin, a compound from Cordyceps militaris, can boost endurance and protect brain function in mice ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

Each cell in your body relies on precise communication with other cells to function properly. At the center of this process ...

Analysts at HC Wainwright issued their Q3 2025 EPS estimates for Rigel Pharmaceuticals in a research report issued to clients ...

Equities research analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Tuesday, March 4th. B. Riley analyst K. Patel expects that ...